How to access Casgevy from Saudi Arabia — the named-patient coordination pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient with severe sickle cell disease — recurrent painful vaso-occlusive crises despite standard therapy — may be evaluated by their treating haematologist for Casgevy (exagamglogene autotemcel, exa-cel). Casgevy is FDA-approved, developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics, and is the first CRISPR-edited cell therapy approved for sickle cell disease (and for transfusion-dependent beta-thalassemia). Because Casgevy is an autologous cell therapy — manufactured individually from each patient's own stem cells — access involves a different pathway than traditional drugs, and typically requires international referral to a qualified cell-therapy treatment centre.
This guide explains the legal and operational pathway, what your haematologist needs to coordinate, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Casgevy is a one-time infusion of genetically edited autologous haematopoietic stem cells, where CRISPR-Cas9 has been used to disrupt a regulatory region and reactivate fetal haemoglobin production. Treatment involves: mobilisation and apheresis to collect stem cells, shipment to the manufacturer, a manufacturing window of several weeks, high-dose myeloablative conditioning chemotherapy, infusion of the edited cells, and an extended inpatient recovery period for engraftment. Eligibility is based on severe sickle cell disease with recurrent crises (or transfusion-dependent beta-thalassemia) and fitness for myeloablative conditioning. Your haematologist will confirm eligibility and identify an authorised treatment centre.
Is Casgevy legally accessible for Saudi patients?
Casgevy cannot be "imported" as a drug — it is manufactured from your own stem cells and must be administered at a Casgevy-qualified cell-therapy treatment centre. Access for Saudi patients, therefore, typically follows one of two patterns, both operating within the Saudi Food and Drug Authority (SFDA) and Ministry of Health medical-referral framework:
Pattern A — Cross-border referral to an authorised cell-therapy centre. The patient travels to a qualified international treatment centre (in the US, Europe, or select Middle-East centres partnering with the manufacturer) for mobilisation, apheresis, conditioning, infusion, and recovery.
Pattern B — Hybrid coordination with a Saudi tertiary centre partnering with Vertex's qualified network. Where a Saudi treatment centre has the cell-therapy infrastructure, portions of the workflow may be localised in coordination with the manufacturer.
The SFDA and MoH medical-referral frameworks support both patterns, with documentation covering medical necessity, treatment-centre identification, and the return-to-home care plan.
How the pathway works, step by step
- Consultation with your haematologist. Eligibility assessment including crisis history, organ-system baseline, and fitness for myeloablative conditioning.
- Treatment-centre identification. Reserve Meds coordinates referral to a Casgevy-qualified treatment centre through our international care-coordination network.
- SFDA / MoH referral documentation. Your physician files the named-patient / medical-referral dossier.
- Mobilisation and apheresis. Conducted at the treatment centre per manufacturer protocol; manufacturing begins after cell collection.
- Manufacturing window (several weeks). Bridging transfusion support and supportive care may be given locally or at the treatment centre.
- Conditioning, infusion, and inpatient engraftment monitoring. Administered at the qualified centre with extended inpatient stay; handover to your Saudi haematologist for long-term follow-up.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, crisis/transfusion history, organ-system status, and Casgevy as the indicated treatment
- Verification of their Saudi medical licence (SCFHS / MOH)
- Identification of the authorised Casgevy treatment centre and the cross-border referral plan
- Patient identifier (anonymised reference where possible)
- A long-term follow-up plan for return to Saudi Arabia
Reserve Meds provides a coordination kit that bundles the templates SFDA reviewers and treatment centres expect to see for cross-border gene-therapy referrals.
Costs and timing
Casgevy's US list price sits in an indicative 2026 range of roughly USD 2.0–2.3 million for the gene-therapy product itself. Total cost of care — including inpatient stay, conditioning, mobilisation, apheresis, engraftment monitoring, and bridging care — typically runs substantially higher when delivered at a US qualified centre. International travel, accommodation for a caregiver, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — from intake to infusion typically runs 12–24 weeks, driven primarily by the manufacturing window and treatment-centre calendar. Inpatient stay around conditioning and engraftment is typically four to six weeks or longer.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: sickle cell disease affects a significant number of Saudi families, particularly in the Eastern Province. Cell-therapy journeys typically require a family caregiver present throughout the extended inpatient stay; our coordination includes caregiver travel, prayer-space orientation, and halal-dining support at the partnering centres.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine and cell therapy. For Casgevy specifically, we provide:
- Treatment-centre referral. Coordination with authorised Casgevy centres through our clinical network.
- Documentation. Cross-border referral and SFDA/MoH named-patient package.
- Logistics. Patient and caregiver travel, accommodation, and post-infusion return-home planning.
- Concierge case lead. A named point of contact for the family throughout the extended treatment journey.
What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the cell product, and we are not the treatment centre. All clinical decisions remain with your treating haematologist and the cell-therapy treatment centre. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA and MoH medical-referral framework with a qualified treatment centre. See our trust and compliance page.
How long will we be abroad? Most Casgevy journeys require 3–6 months away from home, covering workup, mobilisation, manufacturing, conditioning, infusion, and engraftment monitoring. Your treatment centre will confirm.
Is Casgevy a cure for sickle cell disease? Pivotal study data demonstrate durable freedom from vaso-occlusive crises in treated patients. Your haematologist will discuss realistic outcome expectations and the long-term surveillance plan.
What about the conditioning chemotherapy risks? Myeloablative conditioning carries substantial short- and long-term risks including infertility. Fertility preservation counselling is a standard pre-treatment step. Your haematology team will explain the full profile.
Will insurance or MoH coverage apply? Some Saudi patients may receive partial MoH coverage for complex international referrals; we supply documentation for submission but do not process public-payer claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026 for cell-therapy coordination. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Casgevy coordination.
Add me to the Casgevy waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.